Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced that three posters from the Company’s development
pipeline will be presented at the American Academy of Neurology
(AAN) 2024 Annual Meeting taking place April 13-18, 2024, in
Denver, Colorado, USA.
“We are thrilled to be presenting at this
prestigious international neurology conference, including new
baseline biomarker data on ATH434 from our ongoing Phase 2
randomized, double blind clinical trial in multiple system atrophy
(MSA), as well as compelling preclinical primate data on ATH434 in
Parkinson’s disease,” said, David Stamler, M.D., Chief Executive
Officer of Alterity. “In addition, we remain in the vanguard of
biomarker evaluation of MSA, as our partners at Vanderbilt
University will present important data from our bioMUSE natural
history study. AAN promises to be a very productive conference for
us as we advance our MSA program toward data later this year and
expand our development toward Parkinson’s disease.”
Title: |
|
A Phase 2 Study of ATH434, a Novel Inhibitor of α-Synuclein
Aggregation, for the Treatment of Multiple System Atrophy
(MSA) |
Lead Author: |
|
David Stamler, M.D., Chief
Executive Officer of Alterity Therapeutics |
Date/Time: |
|
Sunday, April 14, from 11:45 a.m.
12:45 p.m. Mountain Time (U.S.) |
|
|
|
Title: |
|
Neurofilament Light Chain
and Clinical Progression in Early Multiple System
Atrophy |
Lead Author: |
|
Daniel O. Claassen, M.D., M.S.,
Professor of Neurology, Vanderbilt University Medical Center |
Date/Time: |
|
Monday, April 15, from 5:30 p.m.
to 6:30 p.m. Mountain Time (U.S.) |
|
|
|
Title: |
|
Effects of ATH434, a
Clinical-phase Small Molecule with Moderate Affinity for Iron, in a
Parkinson's Disease Model in Macaques |
Lead Author: |
|
Margaret Bradbury, Vice
President, Research and Nonclinical Development, Alterity
Therapeutics |
Date/Time: |
|
Tuesday, April 16, from 11:45
a.m. to 12:45 p.m. Mountain Time (U.S.) |
|
|
|
About ATH434
Alterity’s lead candidate, ATH434, is an oral
agent designed to inhibit the aggregation of pathological proteins
implicated in neurodegeneration. ATH434 has been shown
preclinically to reduce α-synuclein pathology and preserve neuronal
function by restoring normal iron balance in the brain. As an iron
chaperone, it has excellent potential to treat Parkinson’s disease
as well as various Parkinsonian disorders such as Multiple System
Atrophy (MSA). ATH434 successfully completed Phase 1 studies
demonstrating the agent is well tolerated and achieved brain levels
comparable to efficacious levels in animal models of MSA. ATH434 is
currently being studied in two clinical trials: Study ATH434-201 is
a randomized, double-blind, placebo-controlled Phase 2 clinical
trial in patients with early-stage MSA and Study ATH434-202 is an
open-label Phase 2 Biomarker trial in patients with more advanced
MSA. ATH434 has been granted Orphan drug designation for the
treatment of MSA by the U.S. FDA and the European Commission.
About ATH434-201 Phase 2 Clinical
Trial
The ATH434-201 Phase 2 clinical trial is a
randomized, double-blind, placebo-controlled investigation of
ATH434 in patients with early-stage MSA. The study will evaluate
the effect of ATH434 treatment on neuroimaging and protein
biomarkers to demonstrate target engagement and clinical endpoints
to demonstrate efficacy, in addition to assessments of safety and
pharmacokinetics. Selected biomarkers, such as brain iron and
aggregating α-synuclein, are important contributors to MSA
pathology and are therefore appropriate targets to demonstrate drug
activity. Wearable sensors have also been employed to evaluate
motor activities that are important to patients with MSA. The study
enrolled 77 adults who were randomly assigned to receive one of two
dose levels of ATH434 or placebo. Participants will receive
treatment for 12 months which will provide an opportunity to detect
changes in efficacy endpoints to optimize design of a definitive
Phase 3 study. Additional information on the Phase 2 trial can be
found by ClinicalTrials.gov Identifier: NCT05109091.
About bioMUSE
Biomarkers of progression in Multiple System
Atrophy (bioMUSE) is a natural history study that aims to track the
progression of individuals with MSA, a parkinsonian disorder
without approved therapy. The study is being conducted in
collaboration with Vanderbilt University Medical Center in the U.S.
under the direction of Daniel Claassen, M.D., M.S., Professor of
Neurology and Principal Investigator. Natural history studies are
important for characterizing disease progression in selected
patient populations. The study has provided rich data for
optimizing the design of Alterity’s randomized ATH434-201 Phase 2
clinical trial and enrolled approximately 20 individuals with
clinically probable or clinically established MSA. BioMUSE
continues to provide vital information on early stage MSA patients,
informs the selection of biomarkers suitable to evaluate target
engagement and preliminary efficacy, and delivers clinical data to
characterize disease progression in a patient population that
mirrors those currently enrolling in the Phase 2 clinical
trial.
About Multiple System
Atrophy
Multiple System Atrophy (MSA) is a rare,
neurodegenerative disease characterized by failure of the autonomic
nervous system and impaired movement. The symptoms reflect the
progressive loss of function and death of different types of nerve
cells in the brain and spinal cord. It is a rapidly progressive
disease and causes profound disability. MSA is a Parkinsonian
disorder characterized by a variable combination of slowed movement
and/or rigidity, autonomic instability that affects involuntary
functions such as blood pressure maintenance and bladder control,
and impaired balance and/or coordination that predisposes to falls.
A pathological hallmark of MSA is the accumulation of the protein
α-synuclein within glia, the support cells of the central nervous
system, and neuron loss in multiple brain regions. MSA affects at
least 15,000 individuals in the U.S., and while some of the
symptoms of MSA can be treated with medications, currently there
are no drugs that are able to slow disease progression and there is
no cure.1
1Multiple System Atrophy | National Institute of Neurological
Disorders and Stroke (nih.gov)
About Parkinson’s Disease
Parkinson's disease (PD) is the second most
common neurodegenerative disorder and causes unintended or
uncontrollable movements of the body along with neuropsychiatric
and other nonmotor features. The precise cause of PD is
unknown, but some cases are hereditary while others are thought to
occur from a combination of genetics and environmental factors that
trigger the disease. In PD, brain cells become damaged or die
in the substantia nigra, the part of the brain that produces
dopamine--a chemical needed to produce smooth, purposeful movement.
The cardinal symptoms of PD are tremors, rigidity, slowing of
movements, and later in disease, impaired balance. Other symptoms
may include difficulty swallowing, chewing, or speaking; emotional
changes; urinary problems or constipation; dementia or other
cognitive problems; fatigue; and problems sleeping.1
Nearly one million people in the U.S. and more than 10 million
people worldwide are living with PD. Approximately 60,000 Americans
are diagnosed with PD each year.2
1National Institute of Health: Neurological
Disorders and Stroke, Parkinson's Disease Information Page;
2Parkinson’s Foundation
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
web site at www.alteritytherapeutics.com.
Authorisation & Additional informationThis
announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act
of 1933 and section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "intends," "hopes," "anticipates,"
"believes," "could," "may," "evidences" and "estimates," and other
similar expressions, but these words are not the exclusive means of
identifying such statements.
Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are described in the sections titled
“Risk Factors” in the Company’s filings with the SEC, including its
most recent Annual Report on Form 20-F as well as reports on Form
6-K, including, but not limited to the following: statements
relating to the Company's drug development program, including, but
not limited to the initiation, progress and outcomes of clinical
trials of the Company's drug development program, including, but
not limited to, ATH434, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development,
testing, regulatory approval, production and marketing of the
Company’s drug components, including, but not limited to, ATH434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including,
but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection
for the Company's intellectual property or trade secrets, the
uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2024 to May 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From May 2023 to May 2024